Correlation between egfr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma

Radiation Oncology

Marco Salvatore⁴  Roberto Orecchia¹  Marcello Benassi⁶  Giovanni Storto²  Giuseppina Improta²  Alba Fiorentino²  Rocchina Caivano²  Barbara Vischioni⁵  Francesca Botta⁷  Marta Cremonesi⁷  Daniela Alterio⁷  Barbara Alicia Jereczek-Fossa¹  Lidia Strigari³  Antonio Nappi²  Piernicola Pedicini² 

[1] University of Milan, Milan, Italy;I.R.C.C.S. C.R.O.B.Regional Cancer Hospital, Rionero in Vulture, Italy;Regina Elena National Cancer Institute, Roma, Italy;I.R.C.C.S SDN Foundation, Naples, Italy;Division of Radiation Oncology and Radiobiology, National Center for Oncological Hadrontherapy CNAO, Pavia, Italy;Scientific Institute of Tumours of Romagna I.R.S.T, Meldola, Italy;I.E.O. European Institute of Oncology, Milan, Italy

关键词: Cell loss factor;    Potential doubling time;    Doubling time;    EGFr;   

Others  :  1155392
DOI  :  10.1186/1748-717X-7-143

 received in 2012-03-05, accepted in 2012-07-29,  发布年份 2012

【 摘 要 】

Purpose

To investigate the correlation between the expression of Epidermal Growth Factor receptor (EGFr) and the reduction of the effective doubling time (T_D) during radiotherapy treatment and also to determine the dose per fraction to be taken into account when the overall treatment time (OTT) is reduced in accelerated radiotherapy of head and neck squamous cell carcinoma (HNSCC).

Methods

A survey of the published papers comparing 3-years of local regional control rate (LCR) for a total of 2162 patients treated with conventional and accelerated radiotherapy and with a pretreatment assessment of EGFr expression, was made. Different values of T_D were obtained by a model incorporating the overall time corrected biologically effective dose (BED) and a 3-year clinical LCR for high and low EGFr groups of patients (H_EGFr and L_EGFr), respectively. By obtaining the T_D from the above analysis and the sub-sites’ potential doubling time (T_pot) from flow cytometry and immunohistochemical methods, we were able to estimate the average T_D for each sub-site included in the analysis. Moreover, the dose that would be required to offset the modified proliferation occurring in one day (D_prolif), was estimated.

Results

The averages of T_D were 77 (27-90)_95% days in L_EGFr and 8.8 (7.3-11.0)_95% days in H_EGFr, if an onset of accelerated proliferation T_K at day 21 was assumed. The correspondent H_EGFr sub-sites’ T_D were 5.9 (6.6), 5.9 (6.6), 4.6 (6.1), 14.3 (12.9) days, with respect to literature immunohistochemical (flow cytometry) data of T_pot for Oral-Cavity, Oro-pharynx, Hypo-pharynx, and Larynx respectively. The D_prolif for the H_EGFr groups were 0.33 (0.29), 0.33 (0.29), 0.42 (0.31), 0.14 (0.15) Gy/day if α = 0.3 Gy^-1 and α/β = 10 Gy were assumed.

Conclusions

A higher expression of the EGFr leads to enhanced proliferation. This study allowed to quantify the extent of the effect which EGFr expression has in terms of reduced T_D and D_prolif for each head and neck sub-site.

【 授权许可】

   
2012 Pedicini et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Overgaard J, Alsner J, Eriksen J, et al.: Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck. Rays 2000, 25:313-319.
• [2]Overgaard J, Hansen HS, Specht L, et al.: Five compared with six fractions per week of conventional radiotherapy of squamous cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003, 362:933-940.
• [3]Hansen O, Overgaard J, Hansen HS, et al.: Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumour differentiation. Radioth Oncol 1997, 43:47-51.
• [4]Dassonville O, Forment JL, Francoual M, et al.: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993, 11:1873-1878.
• [5]Eriksen JG, Steiniche T, Askaa J, et al.: The prognostic value of epidermal growth factor receptor is related to tumour differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Rad Onc Bio Phys 2004, 58:561-566.
• [6]Eriksen JG, Steiniche T, Overgaard J, et al.: The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Octa Oncol 2005, 44:50-58.
• [7]Eriksen JG, Alsner J, Steinich T, et al.: The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. Radioth Oncol 2005, 76:135-142.
• [8]Bentzen SM, Atasoy BM, Daley FM, et al.: Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial. J Clin Oncol 2005, 23:5560-5567.
• [9]Suwinski R, Jaworska M, Nikiel B, et al.: Predicting the effect of accelerated fractionation in postoperative radiotherapy for head and neck cancer based on molecular marker profiles: data from a randomized clinical trial. Int J Rad Onc Bio Phys 2010, 77:438-446.
• [10]Smid EJ, Stoter TR, Bloemena E, et al.: The importance of immunohistochemical expression of egfr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy. Int J Rad Onc Bio Phys 2006, 65:1323-1329.
• [11]Chung CH, Zhang Q, Hammond EM, et al.: Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Rad Onc Bio Phys 2011, 81:331-338.
• [12]Tomé WA, Fowler JF, et al.: Selective boosting of tumour subvolumes. Int J Rad Onc Bio Phys 2000, 48:593-599.
• [13]Tucker SL, Thames HD, Taylor JM: How well is the probability of tumour cure after fractionated irradiation described by poisson statistics? Radiat Res 1990, 124:273-282.
• [14]Steel GG: Growth Kinetics of Tumours. Oxford: Clarendon-Press; 1977.
• [15]Wilson GD, Discheb S, Saundersb MI: Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy. Radioth Oncol 1995, 36:189-197.
• [16]Bennett MH, Wilson GD, Dische S, et al.: Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer 1992, 65:870-878.
• [17]Thames HD, Bentzen SM, Turesson I, et al.: Time-dose factors in radiotherapy: a review of the human data. Radioth Oncol 1990, 19:219-235.
• [18]Collett D: Modelling survival data-in medical research. London: Chapman and Hall; 1994:22-26.
• [19]Smith BD, Haffty BG: Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat Oncol Investig 1999, 7:125-144.
• [20]Strigari L, Pedicini P, D'Andrea M, Benassi M: A model for predicting Acute Mucosal Toxicity (AMT) in head and neck cancer patients undergoing radiotherapy with altered schedule. Int J Rad Onc Bio Phys 2012, 83:e697-e702.
• [21]Shi SR, Cote RJ, Chaiwun B, et al.: Standardization of immunohistochemistry based on antigen retrieval technique for routine formalin-fixed tissue sections. Appl Immunohistochem 1998, 6:89-96.
• [22]Fowler JF: Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling. J Clin Oncol 2007, 19:8-22.
• [23]Bentzen SM, Thames HD: Clinical evidence for tumour clonogen regeneration: interpretations of the data. Radioth Oncol 1991, 22:161-166.
• [24]Bentzen SM, Johansen LV, Overgaard J, Thames HD: Clinical radiobiology of squamous cell carcinoma of the oropharynx. Int J Rad Onc Bio Phys 1991, 20:1197-1206.
• [25]Begg AC: The clinical status of Tpot as a predictor? or why no tempest in the Tpot. Int J Rad Onc Bio Phys 1995, 32:1539-1541.
• [26]Pedicini P, Caivano R, Jereczek-Fossa BA, et al.: Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors. Theor Biol Med Model 2012, 9(1):23. 19 BioMed Central Full Text